EUVIMEDEuropean Health Evidence
Uhr Sources10/10 Journal Tree
Easy Demo

European Health Evidence

The European alternative to PubMed

EUVIMED is the European alternative to PubMed: a central, multilingual research platform for medicine, nursing, life sciences and healthcare. It brings together international and European literature sources, study registries, open-access full texts, citations and retraction notices in one search. Unlike pure bibliographic databases, EUVIMED supports the entire research process – from discovery and appraisal with LIVIA and CLARA to traceable evidence synthesis. European in focus, transparent, interoperable and designed for science and healthcare.

EuropeanMultilingualInteroperableTraceable

EUVIMED BETA

EUVIMED is currently in beta

EUVIMED is under continuous development. Features, data coverage and presentation may change or be temporarily incomplete.

Results are beta

Search results, classifications, summaries and AI-assisted assessments may be incomplete, delayed or incorrect.

Check original sources

Do not use EUVIMED results without verification for diagnosis, treatment or other clinical decisions. Always consult the original source and applicable guidelines.

Errors and feedback help us improve EUVIMED: info@euvimed.com

Lokaler Crossref-Datenbestand · journal-article

Bioprinting functional fat – adipocytes as the next frontier in tissue engineering, regenerative medicine, and cultivated meat

Sophia Nowakowski, Anna Leikeim, Paul Gatenholm, Petra J. Kluger

Frontiers in Bioengineering and Biotechnology · 2026

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Adipose tissue is a vital component in both regenerative medicine and cultivated meat, yet the selection of the cellular starting material remains an underexplored determinant of adipose construct performance in bioprinting. This mini-review explores next-generation adipose tissue engineering, emphasizing bioprinting functional fat with adipocytes at the intersection of these two fields. While current adipose bioprinting strategies predominantly rely on adipose-derived stem or stromal cells for their expandability and manufacturability, mature adipocytes (ACs) and microfat emerge as alternative cell sources with distinct advantages in functional fidelity, metabolic relevance, and immediate tissue-like behavior. However, these approaches impose fundamentally different biological and engineering constraints that directly influence biofabrication strategy, biomaterial design, and translational potential. This mini review offers a structured comparison of mature adipocyte-, progenitor-, and microtissue-based strategies, highlighting features that influence biofabrication and applicability. Scalability is identified as a major bottleneck in translation, with a focus on process robustness, batch-to-batch reproducibility, and manufacturing concepts relevant to preclinical test systems, clinical applications, and large-scale cultivated meat (CM) production. By proposing a cell-source-guided framework for adipose bioprinting, this mini review aims to provide a practical decision-making perspective for developing next-generation adipose constructs.

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
Sophia Nowakowski, Anna Leikeim, Paul Gatenholm, Petra J. Kluger
Quelle
Frontiers in Bioengineering and Biotechnology
Publikation
2026-01-01
Band / Ausgabe
Nicht angegeben
Seiten
Nicht angegeben
ISSN / ISBN
2296-4185
Zitationen
0 laut Crossref
Referenzen
0 hinterlegt

Zitieren

Zitierfähiger Nachweis

Sophia Nowakowski, Anna Leikeim, Paul Gatenholm, Petra J. Kluger (2026). Bioprinting functional fat – adipocytes as the next frontier in tissue engineering, regenerative medicine, and cultivated meat. Frontiers in Bioengineering and Biotechnology. https://doi.org/10.3389/fbioe.2026.1923018
RIS BibTeX CSL-JSON

Kontext

Themen, Förderung und Nutzung

Lizenzhinweise: Lizenz 1